

AR 226 - 0622

December 9, 1998

3M

Charles M. Auer, Director
Chemical Control Division
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460

RECEIVED
OPPT NCIC
2000 SEP - 6 PM 12:56

Dear Mr. Auer:

Enclosed is our proposed agenda for the 3M meeting with EPA on Monday, December 14, 1998 from 1:00 - 2:00 p.m. The purpose of the meeting is to give an overview of the issues surrounding the TSCA 8(e) filing in May, 1998 regarding the finding of perfluorooctane sulfonate in blood samples from the general population. The following individuals will be in attendance from 3M:

Dr. Charles (Chuck) Reich	Group Vice President	Chemical Markets Group
Dr. William (Bill) Weppner	EHS&R Director	Chemical Markets Group
Mr. Daniel (Dan) Hakes	Product Steward Specialist	Chemical Markets Group
Dr. Larry Zobel	Staff Vice President	3M
	And Medical Director	

We have developed the following agenda to fit within the scheduled meeting time of one hour.

Introduction and General Comments	Dr. Charles Reich
Product Overview	Dr. Weppner
Toxicology and Human Health Data	Dr. Zobel
Environmental Exposure Assessments/Product Stewardship	Dr. Weppner
Discussion	All

By this meeting, we hope to begin working in partnership with the agency to review our testing activities and stewardship plans and to solicit agency input on our efforts. At the end of the hour we would like to develop a defined structure for follow up, including identifying a primary contact at the agency and scheduling working group sessions to review the science and our testing program in more detail.

Please feel free to contact me in advance of the meeting if you have any questions or comments.

Best regards,

William A. Weppner

William A. Weppner, Ph.D.

Director

Environmental, Health, Safety & Regulatory Affairs

Chemical Markets Group

3M Center, Bldg. 236-1B-10

St. Paul, MN 55144

651/733-6374